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(Weterman et al., 1996). Different signal-
ing patterns present in tumors are based 
on the status of the p53 versus p16ink4a 
tumor suppressor genes (Arbiser, 2004), 
and it would be valuable to know wheth-
er mutations in p53 versus inactivation of 
p16ink4a predominate in keratinocyte 
clones that undergo spontaneous immor-
talization and whether the presence or 
absence of VEGF biases p53 mutation 
versus p16ink4a loss.
In the study by Mirones et al., the 
clones were transformed by oncogenic 
ras and further differences were noted. 
The ability of transformed cells to form 
colonies in soft agar was significantly dif-
ferent from that of wild-type cells, with 
the VEGF-proficient cells demonstrating 
increased proficiency in soft agar growth. 
We have previously demonstrated that 
soft agar growth is an accurate measure 
of MAP kinase (p42/44 ERK) activation, 
which does not always correlate with 
in vivo tumorigenicity (LaMontagne et 
al., 2000). I therefore predict that the 
increased ability of wild-type tumor cells 
to form colonies in soft agar represents 
increased MAP kinase activation. The 
disparity in soft agar colony formation 
highlights another difference in the tumor 
cells because it occurs in the absence of 
endothelial cells, confirming an angio-
genesis-independent effect. One would 
predict that the addition of a VEGF inhibi-
tor might decrease the ability of wild-type 
tumor cells to form colonies in soft agar.
Transformed cells were implanted 
into nude mice. Both genotypes were 
capable of forming tumors in nude mice, 
but VEGF-proficient cells were much 
more proficient in tumor formation, and 
rapidly growing tumors were apparent. 
Surprisingly, the tumors differed pri-
marily in terms of bromodeoxyuridine 
incorporation, a marker of proliferation, 
rather than in rates of apoptosis. This dif-
fers from the observations regarding pure 
angiogenesis blockade, as demonstrated 
by Holmgren et al., in which blockade of 
Lewis lung carcinoma with angiostatin 
resulted in a massive increase in apopto-
sis, with no significant change in tumor 
proliferation. The histologic appearance 
of the VEGF-proficient tumors versus the 
VEGF-deficient tumors is consistent with 
the bromodeoxyuridine findings, with 
a much more cellular tumor present in 
the VEGF-proficient tumors. Finally, the 
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Mirones et al. demonstrate that keratinocytes deficient in VEGF are capable of 
forming tumors but use a distinct form of aneuploidy and signaling to form tumors. 
This knowledge is important because inhibitors of VEGF, including bevacizumab 
(anti-VEGF antibodies) and sorafenib (Braf/VEGFR2 kinase inhibitor), have already 
entered the clinic. These agents may "remodel" tumor signaling.
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Vascular endothelial growth factor 
(VEGF) is a potent mediator of angio-
genesis. Initially isolated as a vascular 
permeability factor, VEGF was found to 
be a potent endothelial chemoattractant, 
and it is present in the vast majority of 
neoplastic and inflammatory processes 
(Brown et al., 2000). VEGF binds as a 
dimer and signals through VEGFR1, -R2, 
and -R3 (Matsumoto and Mugishima, 
2006; Holmqvist et al., 2004). The most 
studied receptor is VEGFR2, which acti-
vates several signaling pathways, includ-
ing phosphoinositol-3 kinase/akt and 
mitogen-activated protein (MAP) kinase, 
and mediates most known effects of 
VEGF and VEGFR3, which is predomi-
nantly located on lymphatic endothe-
lium. Based on the potent angiogenic 
effects of VEGF, inhibitors of VEGF have 
been developed, including antibodies, 
traps, and small-molecule tyrosine kinase 
inhibitors. One of these, bevacizumab 
(Avastin), has been approved by the US 
Food and Drug Administration and is 
extensively used in renal cell carcinoma 
as well as in breast, lung, and colon carci-
noma. It has been shown to prolong life, 
not as monotherapy but in combination 
with chemotherapy (Willett et al., 2004; 
Hurwitz et al., 2004; Ramaswamy et al., 
2006). The rationale behind these obser-
vations is that by reducing vascular leak, 
bevacizumab increases local delivery of 
chemotherapeutic agents.
The report of Mirones et al. (2009, this 
issue) highlights an unexpected autocrine 
role of VEGF in squamous cell carcino-
ma. The authors used transgenic mice in 
which exon 3 of VEGF was surrounded by 
lox sites, and they used an adenoviral Cre 
to excise exon 3, resulting in keratino-
cytes that were deficient in VEGF. These 
keratinocytes were spontaneously immor-
talized in culture, as were keratinocytes 
that produce VEGF, and then assayed for 
in vitro growth, spectral karyotyping, soft 
agar growth, in vivo growth, and the abil-
ity to colonize the lungs when injected 
into tail veins. In virtually all these assays, 
both in vitro and in vivo, significant differ-
ences were observed between the VEGF-
deficient and -proficient cell lines. These 
results highlight autocrine roles for VEGF, 
as well as VEGF-independent modes 
of vascularization. Karyotypic analysis 
of both VEGF-proficient and -deficient 
cells shows aneuploidy, although dif-
ferent patterns are apparent in both cell 
lines. Although continued passage in 
cell culture is known to cause sponta-
neous immortalization and aneuploidy, 
one can speculate that the presence or 
absence of VEGF might influence the 
pattern of aneuploidy. Despite the com-
plexity of the spectral karyotypes, recent 
studies have shown that aneuploidy is 
anything but random, with the discovery 
of recurrent translocations in epithelial, 
mesenchymal, and hematopoietic tumors 
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ability of VEGF-deficient cells to colonize 
and form tumors in the lung is compro-
mised compared with that of proficient 
cells. Although intravascular injection of 
tumor cells does not completely recapit-
ulate the metastatic process in that tumor 
cells do not migrate from their primary 
site, intravascular injection is a measure 
of the ability of tumor cells to survive in 
suspension in the bloodstream (anoikis) 
plus the ability to extravasate from the 
bloodstream and develop into secondary 
tumors. All these observations are consis-
tent with an angiogenesis-independent 
effect of VEGF on tumor cells.
It was recently discovered that human 
carcinoma cells with mutant Ras dem-
onstrate paradoxical Ras activation upon 
serum deprivation (Garcia et al., 2008; 
Zheng et al., 2006). Important compo-
nents of serum are growth factors, which 
include VEGF. Serum-deprived Ras acti-
vation is accompanied by increased 
phospholipase D activity, resulting in the 
generation of phosphatidic acid and pre-
vention of apoptosis (Zhong et al., 2003; 
Garcia et al., 2008). Thus, tumors with 
oncogenic ras may be protected against 
tyrosine kinase inhibition through activa-
tion of a ras–phospholipase D pathway. 
This phenotype has been termed the 
serum deprivation phenotype (Figure 1), 
and it is blocked by the small-molecular-
weight ras inhibitor honokiol. Loss of 
autocrine VEGF probably causes activa-
tion of the serum-deprivation phenotype.
These cells offer a valuable model with 
which to answer several questions about 
tumorigenicity. For instance, VEGF occurs 
in at least three isoforms of 121, 164, and 
188 amino acids in the mouse, as a result 
of alternate splicing. It would be valuable 
to introduce each isoform individually to 
identify those that are required for tumori-
genicity. VEGF 121 is almost exclusively 
secreted, 164 is partially membrane 
bound, and 188 is almost exclusively 
membrane bound. We have previously 
demonstrated that VEGF 121 causes 
autocrine transformation of endothelial 
cells to a slow-growing angiosarcoma 
(Arbiser et al., 2000). Finally, compari-
son of the signaling pathways present in 
VEGF-deficient versus -proficient tumors 
is of clinical relevance. Tyrosine kinase 
inhibitors have been shown to have effi-
cacy against lung cancers, but only in the 
absence of ras mutations. These paired 
cell lines might shed light on the signal-
ing differences that tyrosine kinase acti-
vation plays in tumor cells, because both 
cell types have the same ras mutation. 
Candidate signaling pathways that might 
differ between the cell lines include acti-
vation of phosphoinositol-3 kinase/akt, 
reactive oxygen/rac, stat 1 and 3, src, 
sonic hedgehog, notch, and p42/44 MAP 
kinase. These differences could be rapidly 
assessed by western blot analysis.
These findings strikingly illustrate a 
central question in clinical medicine—
why solid tumors use both tyrosine 
kinase activation and ras mutation to 
become aggressive when either tyrosine 
kinase activation or ras activation alone is 
sufficient (Arbiser, 2007). They also illus-
trate that the combination of ras block-
ade with tyrosine kinase blockade will 
be required to address the resistance of 
solid tumors to tyrosine kinase blockade. 
New small molecules such as honokiol 
target ras activation, and they may syner-
gize with tyrosine kinase inhibitors in the 
treatment of solid tumors (Garcia et al., 
2008).
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Woolly Antics between the Sheaths
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Hair is a potent cultural signal that when perceived as deficient can invite psy-
chological trauma. Over the past few decades, researchers have successfully 
dissected several controls for hair follicle development and growth. However, 
we know relatively little about the genetic controls for hair fiber form and 
texture, despite wide variability in the expression of hair phenotypes among 
different, even very closely related, individuals. In this issue, Shimomura et al. 
present some intriguing insights into the potential role for lipase H in the con-
trol of hair form and texture.
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The form and color of scalp hair play 
significant roles in human culture. It is 
therefore not surprising that significant 
psychological trauma is associated 
with hair “problems,” including too 
much or too little hair or the “wrong” 
type or color. Much has been written 
about the more common alopecias, 
including androgenetic alopecia, telo-
gen effluvium, alopecia areata, and 
iatrogenic alopecias. However, apart 
from miniaturization (e.g., androge-
netic alopecia) and fracturing (e.g., 
iatrogenic alopecia) of the fiber, these 
conditions provide little insight into 
the genetic controls of physiological 
hair form and texture.
Hair texture: a fragile trait
The terminal hair shaft, as best exem-
plified by human scalp hair, consists of 
an outer cuticle ensheathing an inner 
cortex (sometimes with an additional 
core medulla). This remarkable bio-
physical composite is constructed via 
a highly integrated system of compo-
nents, including, in order of decreasing 
amount, keratins, keratin-associated 
proteins, water, lipids, melanin, and 
trace elements. Most researchers of hair 
structure have focused attention on the 
biosynthesis center of the hair follicle, 
spanning from the bulb to the kerato-
genous zone—about 500 µm above 
the zone of maximal keratinocyte 
proliferation. Others have studied the 
genetic control of hair form and texture 
by examining the significant variability 
among humans of different ethnicities. 
Most of these studies have revealed 
a remarkably uniform chemical 
composition of hair protein across eth-
nic groups. Indeed, a systematic exami-
nation of protein structure of hairs from 
Asian (mongoloid), Caucasian, and 
African individuals revealed no differ-
ences by X-ray analysis in the structure 
of the hair keratin, and there are also 
no significant differences in amino acid 
composition of hair of different ethnici-
ties (Franbourg et al., 2003).
The usual suspects for directing hair 
form and texture have been sought 
among the keratin intermediate fila-
ment (KIF) and keratin-associated pro-
tein (KAP) gene families. This is not 
surprising, given that almost half of 
all keratins expressed in epithelia are 
expressed specifically in the hair fol-
licle. Several mouse mutations with 
hypotrichotic causation map to KIF 
or KAP genes. Prominent examples 
include the congenital hair disorder 
monilethrix, which results from muta-
tions in at least three type II hair cortex 
keratins (Winter et al., 1997). Defective 
hair fiber formation can also be seen 
in the nude phenotype (nu/nu), where 
there is a loss of expression of keratin 
genes (rather than their mutation). The 
latter instead results from a mutation in 
the winged-helix-nude (WHN) FOXN1 
gene, which encodes a transcriptional 
regulator of hair keratin genes. The nude 
phenotype exhibits reduced cysteine-
rich protein content, which severely 
weakens the hair fiber. Hair fragility 
is also linked with the kinked hair of 
Menkes’ syndrome, in which a copper 
deficiency is somehow associated with 
keratinization abnormalities of the hair 
shaft—perhaps via impaired formation 
of disulfide cross-links in keratin—that 
appear secondary to the dysfunction of 
copper-dependent enzymes. These and 
similar conditions may not tell us much 
about the normal genetic controls for 
hair form and texture.
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